News
1hon MSN
India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...
Swoopes is one of the true pioneers of women’s basketball. She was the first player signed to the WNBA in 1997, led the Houston Comets to four straight championships, and was a cornerstone of Team USA ...
The FDA has issued a warning as fake Ozempic have started circulating amid a recent trend seeing people using the diabetes ...
India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...
Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...
I want you to know I don’t want Novo Nordisk… and the reason that is because if there’s going to be talk about tariffs on ...
Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, drawn by strong cash-flow yields and the prospect of U.S. rate cuts ...
7h
Zacks Investment Research on MSNAmgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...
A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results